Skip to content

Study · Not a test of the peptide alone · 2024

3 results

The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity: a systematic review.

Asiabar AS, Rezaei MA, Jafarzadeh D, Rajaei S, Atefimanesh P, Soleimanpour S, Meher MHK, Azari S

European journal of clinical pharmacology10 Sept 2024Cited by 12 (Europe PMC)

PMID39254692 (opens in a new tab)DOI10.1007/s00228-024-03755-w (opens in a new tab)PepBankPUB-39254692
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneSystematic reviewOther

    In adults and adolescents with overweight or obesity, semaglutide gave more QALYs and higher costs than phentermine-topiramate, phentermine and naltrexone-bupropion.

    In plain wordsIn cost studies, semaglutide gave more healthy years than some other weight-loss drugs but cost more.

    Peptide
    Semaglutide
    Outcome
    IncreaseQALYs versus other anti-obesity drugs
    Study

    n: not reported in source

    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    The current systematic review showed that semaglutide provides more QALYs and creates more costs in comparison with phentermine-topiramate, phentermine, and naltrexone-bupropion.
    1 context sentence
    Summary · context
    The present study aimed to systematically collect and synthesize available cost-effectiveness studies of semaglutide in patients with obesity or overweight in comparison with other interventions.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  2. 02HumanNot a test of Semaglutide aloneSystematic reviewOther

    In patients with class I, II and III obesity, semaglutide created higher total cost than conventional interventions.

    In plain wordsIn cost studies, semaglutide cost more in total than conventional treatments for obesity.

    Peptide
    Semaglutide
    Outcome
    IncreaseTotal cost versus conventional interventions
    Study

    n: not reported in source

    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Results show that semaglutide creates higher total cost compared to conventional interventions in patients with class I, II, and III obesities.
    1 context sentence
    Summary · context
    The present study aimed to systematically collect and synthesize available cost-effectiveness studies of semaglutide in patients with obesity or overweight in comparison with other interventions.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  3. 03HumanNot a test of Semaglutide aloneSystematic reviewOther

    Semaglutide appeared cost-effective versus diet and exercise and versus liraglutide, but not versus sleeve gastrectomy, endoscopic sleeve gastroplasty and gastric bypass.

    In plain wordsIn cost studies, semaglutide looked cost-effective compared with diet and exercise and with liraglutide, but not compared with some surgeries.

    Peptide
    Semaglutide
    Outcome
    MixedCost-effectiveness versus diet and exercise, liraglutide and surgery
    Study

    n: not reported in source

    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Semaglutide appears to be cost-effective versus diet and exercise (D&E) and liraglutide but it was not cost-effective versus sleeve gastrectomy, endoscopic sleeve gastroplasty, and gastric bypass.
    1 context sentence
    Summary · context
    The present study aimed to systematically collect and synthesize available cost-effectiveness studies of semaglutide in patients with obesity or overweight in comparison with other interventions.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.